Published in Kidney Int on February 01, 2010
Paraproteinemia-associated pseudohypercreatininemia across different analytical methodologies. Kidney Int (2010) 0.78
The pH of chemistry assays plays an important role in monoclonal immunoglobulin interferences. Pract Lab Med (2015) 0.75
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) (2005) 4.96
Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med (2015) 4.78
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest (2004) 3.89
Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA (2009) 3.83
A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A (2003) 3.82
High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation (2008) 3.46
Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med (2007) 3.35
Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med (2012) 3.31
Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol (2005) 3.05
The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med (2003) 2.94
RAGE signaling sustains inflammation and promotes tumor development. J Exp Med (2008) 2.51
A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J (2007) 2.44
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 2.43
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes (2008) 2.41
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis (2008) 2.33
Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J (2008) 2.26
Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock (2009) 2.26
Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke (2011) 2.20
Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Crit Care Med (2008) 2.18
A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol (2008) 2.17
Preparation of the dialysis patient for transplantation. Nephrol Dial Transplant (2002) 2.10
Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood (2011) 1.97
Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest (2004) 1.92
Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury - a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEnts. Crit Care (2012) 1.90
The junctional adhesion molecule-C promotes neutrophil transendothelial migration in vitro and in vivo. J Biol Chem (2004) 1.89
Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy. Blood (2011) 1.83
Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell (2008) 1.81
Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol (2013) 1.78
Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin Chem (2006) 1.75
RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol (2009) 1.72
RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect (2004) 1.63
Surgical versus medical treatment of type 2 diabetes mellitus in nonseverely obese patients: a systematic review and meta-analysis. Ann Surg (2015) 1.62
Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care (2005) 1.62
Hantavirus infection. J Am Soc Nephrol (2005) 1.60
Dysregulated cytokine responses during cytomegalovirus infection in renal transplant recipients. Transplantation (2008) 1.55
Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia. Thromb Haemost (2013) 1.53
Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation (2004) 1.52
Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem (2008) 1.52
Microvesicles of women with gestational hypertension and preeclampsia affect human trophoblast fate and endothelial function. Hypertension (2013) 1.52
Malignancy in renal transplantation. J Am Soc Nephrol (2004) 1.50
Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int (2012) 1.47
Caveolin-1-dependent apoptosis induced by fibrin degradation products. Blood (2008) 1.47
sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res (2007) 1.47
Urinary proinflammatory cytokine response in renal transplant recipients with polyomavirus BK viruria. Transplantation (2009) 1.47
AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis. J Leukoc Biol (2009) 1.45
C. elegans as model for the study of high glucose- mediated life span reduction. Diabetes (2009) 1.45
Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood stem cell transplantation. Ann Hematol (2007) 1.44
Evidence of left ventricular contractile asynchrony by echocardiographic phase imaging in patients with type 2 diabetes mellitus and without clinically evident heart disease. Am J Cardiol (2006) 1.44
Overexpression of activated protein C is detrimental during severe experimental gram-negative sepsis (melioidosis). Crit Care Med (2013) 1.43
Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens (2008) 1.42
Platelets contribute to postnatal occlusion of the ductus arteriosus. Nat Med (2009) 1.41
Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. Transplantation (2010) 1.41
RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs (2006) 1.40
Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol (2006) 1.40
The living kidney donor: giving life, avoiding harm. Nephrol Dial Transplant (2003) 1.40
Association of COLIA1 Sp1 polymorphism with the effect of subcutaneously injected recombinant hGH in GH-deficient adults. Pharmacogenomics (2008) 1.39
Improved rejection prophylaxis with an initially intensified dosing regimen of enteric-coated mycophenolate sodium in de novo renal transplant recipients. Transplantation (2011) 1.39
Acute phase reaction to gadolinium-DTPA in dialysis patients. Nephrol Dial Transplant (2008) 1.39
The spectrum of systemic immune alterations after murine focal ischemia: immunodepression versus immunomodulation. Stroke (2009) 1.38
Bench-to-bedside review: The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care (2008) 1.34
Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J Immunol (2008) 1.32
RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation? J Alzheimers Dis (2009) 1.31
Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol (2003) 1.30
Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial. Am J Kidney Dis (2011) 1.27
Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabetes Care (2008) 1.26
The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol (2009) 1.25
Impaired islet turnover in human donor pancreata with aging. Eur J Endocrinol (2008) 1.24
Activation of tubular epithelial cells in diabetic nephropathy. Diabetes (2002) 1.24
Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol (2007) 1.23
Hantavirus infection: an emerging infectious disease causing acute renal failure. Kidney Int (2012) 1.22
Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis (2005) 1.21
Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes (2003) 1.19
Regulation of neovascularization by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis. FASEB J (2004) 1.17
Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. Blood (2011) 1.17
Receptors for advanced glycation end-products targeting protect against hyperoxia-induced lung injury in mice. Am J Respir Cell Mol Biol (2009) 1.16
Proximal neuropathic lesions in distal symmetric diabetic polyneuropathy: findings of high-resolution magnetic resonance neurography. Diabetes Care (2011) 1.16
Sirolimus in renal transplantation. Nephrol Dial Transplant (2007) 1.15
RAGE and ICAM-1 cooperate in mediating leukocyte recruitment during acute inflammation in vivo. Blood (2010) 1.14
Posttranslationally modified proteins as mediators of sustained intestinal inflammation. Am J Pathol (2006) 1.13
Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J (2006) 1.12
Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proc Natl Acad Sci U S A (2012) 1.11
Insulin stimulates the clonogenic potential of angiogenic endothelial progenitor cells by IGF-1 receptor-dependent signaling. Mol Med (2008) 1.11
High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br J Haematol (2004) 1.11
Sustained effects of a mindfulness-based stress-reduction intervention in type 2 diabetic patients: design and first results of a randomized controlled trial (the Heidelberger Diabetes and Stress-study). Diabetes Care (2012) 1.11
Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther (2008) 1.09
The German Chronic Kidney Disease (GCKD) study: design and methods. Nephrol Dial Transplant (2011) 1.09
Antifibrotic actions of mycophenolic acid. Clin Transplant (2006) 1.08
Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. Diabetes Care (2004) 1.08
Vascular endothelial growth factor (VEGF)-induced up-regulation of CCN1 in osteoblasts mediates proangiogenic activities in endothelial cells and promotes fracture healing. J Biol Chem (2007) 1.08